Patents
Literature
121 results about "Virosome" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A virosome is a drug or vaccine delivery mechanism consisting of unilamellar phospholipid membrane (either a mono- or bi-layer) vesicle incorporating virus derived proteins to allow the virosomes to fuse with target cells. Viruses are infectious agents that can replicate in their host organism, however virosomes do not replicate. The properties that virosomes share with viruses are based on their structure; virosomes are essentially safely modified viral envelopes that contain the phospholipid membrane and surface glycoproteins. In clinically designed virosomes, the viral genetic material are substituted with therapeutic agents. As a drug or vaccine delivery mechanism they are biologically compatible with many host organisms and are also biodegradable. The use of reconstituted virally derived proteins in the formation of the virosome allows for the utilization of what would otherwise be the immunogenic properties of a live-attenuated virus, but is instead a safely killed virus. A safely killed virus can serve as a promising vector because it won’t cause infection and the viral structure allows the virosome to recognize specific components of its target cells.
Classical swine fever virus subunit vaccine and preparation method thereof
PendingCN119424626Aimprove immunityHigh expressionPolypeptide with localisation/targeting motifSsRNA viruses positive-sensePig farmsClassical swine fever virus CSFV
The invention provides a classical swine fever virus subunit vaccine and a preparation method thereof, the classical swine fever virus subunit vaccine is based on an E2 protein gene and a GP67 signal peptide gene of a CSFV 1.1 strain, a recombinant expression vector is constructed through gene cloning, a classical swine fever virus E2 recombinant protein is obtained through expression of an insect baculovirus system, and the classical swine fever virus subunit vaccine is obtained. And the recombinant protein is combined with a colloidal manganese adjuvant to prepare the swine fever virus subunit vaccine. The hog cholera virus E2 recombinant protein is close to natural E2 protein in structural function, high in reduction degree, high in expression quantity and suitable for vaccine production and application; the vaccine can generate specific humoral immunity and relatively strong cellular immunity, and is beneficial to removal of CSFV in an animal body; meanwhile, the vaccine can be distinguished from attenuated vaccine strain immunization or wild strain infection at the nucleic acid level, can be used for preventing and purifying classical swine fever in an intensive pig farm, and has a considerable application prospect.
Owner:GIANTSTAR FARMING & ANIMAL HUSBANDRY CORP LTD
Medical solid waste-based geopolymer material as well as preparation method and application thereof
The invention relates to the technical field of building materials, and particularly discloses a medical solid waste-based geopolymer material as well as a preparation method and application thereof. The medical solid waste-based geopolymer material comprises an interface modified bandage, an ultraviolet radiation modified infusion apparatus, iron tailing slag, ceramic slag, an alkali-activated solution and an enhancer. A hypochlorous acid solution is adopted to soak and disinfect the bandage, hypochlorous acid can kill pathogenic microorganisms, and generated chloride ions can also change osmotic pressure of bacteria and virions, so that cells of the bacteria and virions are inactivated; the disinfection bandage is subjected to interface adjustment, so that the cohesiveness of bandage fibers and a matrix can be improved; the infusion apparatus is subjected to ultraviolet radiation, so that the surface roughness of the infusion apparatus can be increased while disinfection and sterilization are performed, the cohesiveness of the infusion apparatus and a matrix interface is improved, and the infusion apparatus can be better integrated into a matrix. The cyclic utilization of the medical solid waste is realized, and the medical solid waste-based geopolymer material has excellent mechanical properties, and has certain environmental benefits and use values when being used in prefabricated building materials.
Owner:SHIJIAZHUANG TIEDAO UNIV
Method for rapidly rescuing bovine coronavirus epidemic strain and application thereof
The invention discloses a method for quickly rescuing bovine coronavirus epidemic strains and application of the method. The bovine coronavirus SHZ isolate is subjected to efficient segmented cloning, the obtained segment and a Linker sequence are subjected to a cyclic polymerase extension reaction, and the obtained reaction product can be directly transfected to 293T cells for virus packaging without purification. Different from a traditional method, the method does not need to amplify full-length virus cDNA clone by means of bacteria and yeast, but directly obtains a sufficient amount of preliminary products through PCR, and avoids the problems of instability and low efficiency when partial sequences of a virus genome proliferate in a bacteria or yeast host. By adopting the reverse genetic system, the recombinant bovine coronavirus expressing the foreign protein is successfully rescued, a brand new technical platform is provided for dynamic visualization research of in-vivo and in-vitro replication of the virus, and an efficient and flexible tool is also provided for virology research, development of virus vector vaccines and screening of antiviral drugs.
Owner:SANYA INSTITUTE OF NANJING AGRICULTURAL UNIVERSITY +2
Preparation method of triple detection kit for influenza A, influenza B and new coronavirus antigens
ActiveCN119438583AFully combinedGuaranteed SolubilityBiological material analysisAgainst vector-borne diseasesAntigen testingRespiratory virus
The invention discloses a preparation method of a triple detection kit for influenza A, influenza B and new coronavirus antigens, and belongs to the field of respiratory virus in-vitro detection. In the antibody labeling stage, the antigen and the antibody can be more sufficiently combined in a manner of adding the linking arm, so that the antigen detection sensitivity can be improved. In the metal spraying stage, a novel coronavirus monoclonal antibody, an influenza A virus monoclonal antibody and an influenza B virus monoclonal antibody marked by latex microspheres are sequentially subjected to multi-layer metal spraying at the same position by a metal spraying instrument, the two antibodies are isolated by a trehalose solution, and metal spraying of three layers of antibodies isolated from each other is completed. And the cross reaction between different antibodies of the conjugate pad in the storage process is avoided, so that non-specific binding is avoided, and the storage stability is improved. The detection kit prepared by the method can specifically detect the novel coronavirus, the influenza A virus and the influenza B virus, and has the advantages of high sensitivity, good repeatability and the like.
Owner:BAODING ABIORES CHIP CO LTD +1
Synthetic combinatorial AAV3 capsid library
Compositions and methods for producing modified AAV Cap genes and combinatorial libraries of chimeric AAV vectors and virions in an AAV serotype 3 background. Selecting for modified AAV3 virions displaying cell- or tissue-specific tropisms differing from WT AAV3. Using the synthetic combinatorial AAV3 capsid libraries for introducing into a selected target host cells one or more nucleic acid molecules useful in diagnostic and / or therapeutic gene-therapy regimens.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC
Influenza A virus culture medium containing zinc ions and preparation method
The invention relates to the technical field of biology, and aims to provide a zinc ion-containing influenza A virus culture medium and a preparation method thereof. The culture medium contains a serum-free cell culture medium, water, a PBS (Phosphate Buffer Solution), bovine serum albumin with the final concentration of 20g / L, TPCK-Trypsin with the final concentration of 2mu g / mL and zinc ions with the final concentration of 0.009-0.015 mmol / L. According to the invention, zinc ions which are originally considered to generate a virus inhibition effect under a relatively low concentration condition can be used for promoting virus replication after the use concentration range is adjusted; therefore, a brand-new culture medium which can be applied to research on common cell models and virus in-vitro culture models of the influenza A virus is provided, and a new solution is provided for optimizing a vaccine production process. The culture medium is simple in formula and convenient to prepare; all the raw material components are common consumables in laboratories, and the required liquid components can be prefabricated in advance and refrigerated for later use; and large-scale vaccine production can be supported.
Owner:ZHEJIANG UNIV
Adeno-associated virus with engineered capsid
The present disclosure provides engineered adeno-associated capsid proteins and recombinant virus vectors comprising an engineered capsid protein, and uses thereof. In some embodiments, the present dislosure provides engineered AAV9 capsid proteins. In particular, the disclosure provides AAV (e.g., AAV9) virions comprising an engineered AAV capsid protein that achieves increased transduction efficiency in heart, increased heart-to-liver ratio, and / or other desirable properties.
Owner:TENAYA THERAPEUTICS INC
Optimized expression cassettes for gene therapy
PendingUS20250049959A1Cell receptors/surface-antigens/surface-determinantsVectorsOpen reading frameNucleotide
In some aspects, cardiac-specific expression cassettes are provided herein. In some aspects, provided herein is an expression cassette comprising a polynucleotide sequence encoding a gene product for therapy of a heart disease, wherein the polynucleotide sequence is operably linked to promoter (e.g., a cardiac-specific promoter), and optionally an enhancer (e.g., a cardiac-specific enhancer). In some aspects, the disclosure provides recombinant adeno-associated virus (rAAV) virions, comprising a capsid protein and a viral genome comprising an expression cassette comprising a polynucleotide sequence encoding a therapeutic gene product, e.g., dwarf open reading frame (DWORF) polypeptide, operably linked to a promoter, the expression cassette flanked by inverted terminal repeats. The disclosure further provides pharmaceutical compositions and methods of treating or preventing heart disease.
Owner:TENAYA THERAPEUTICS INC
TCR-T cell preparation method and product thereof
PendingCN119331907Aachieve preparationachieve transformationImmunoglobulin superfamilyGenetically modified cellsVirosomeMrna transfection
The invention relates to a TCR-T cell preparation method and a TCR-T cell product. The preparation method of the TCR-T cell provided by the invention comprises a step of introducing annular mRNA (messenger Ribonucleic Acid) into a T cell modified by a non-T cell receptor gene; and, the cyclic mRNA comprises a first cyclic mRNA encoding a T cell receptor; in addition, the first annular mRNA comprises the following sequence (a) or (b): (a) a translation starting sequence and a coding sequence; and (b) translating the starting sequence, the coding sequence and the insertion element sequence. In the method, the transfection efficiency of the annular mRNA is high; compared with a virus system and the like, the process is extremely simple, and the production cost and the detection cost are greatly reduced; compared with linear mRNA, the protein expression time is greatly prolonged; compared with a virus system, a transposon system and a CRISPR system, the safety risk is greatly reduced.
Owner:GUANGZHOU YIDA HEALTH MANAGEMENT TECHNOLOGY CO LTD
SYSTEMS AND METHODS USING SULFATED GLYCOSAMINOGLYCANS (GAGs) AND GAG ANALOGS TO TREAT OR PREVENT MONKEYPOX (MPOX)
A composition is orally or topically administered to a patient susceptible to infection by an orthopoxvirus such as monkeypox (mpox). The composition includes inhibitors configured to bind to orthopoxvirus envelope proteins, e.g., MPXV A29 from mpox. The inhibitors can include sulfated polysaccharides or glycans such as heparin, chondroitin sulfate A, chondroitin sulfate B (dermatan sulfate), chondroitin sulfate C, chondroitin sulfate D, chondroitin sulfate E, pentosan polysulfate, mucopolysaccharide polysulfate, or combinations thereof. Binding of the composition to the envelope proteins inhibits the interaction between the virions and heparan sulfate proteoglycans (HSPG) and thus the ability of the virions to enter the host cell. Limiting this transport across the host cell membrane inhibits initial viral infection, as well as limits spread of that infection from cell to cell even in the event viral infection is initially achieved, providing significantly improved patient treatment and recovery outcomes relating to orthopoxvirus infections such as mpox.
Owner:RENESSELAER POLYTECHNIC INST
Adeno-associated virus with engineered capsid
The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein identified using a high-throughput sequencing screen or rational design. In particular, the disclosure provides AAV5 virions and capsid proteins with increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.
Owner:TENAYA THERAPEUTICS INC
Adeno-associated virus virions with variant capsid and methods of use thereof
The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
Owner:RGT UNIV OF CALIFORNIA
Cell strain for producing engineered virus-like particles, method thereof and engineered virus-like particles
The invention provides a cell strain for producing engineered viroid particles, a method thereof and the engineered viroid particles, the cell strain is named as SZCV-Con28 and preserved in Guangdong Microbial Culture Collection Center on October 15, 2025, the preservation number is GDMCC No: 67101, and the preservation number is GDMCC No: 67101. A plurality of corresponding cell factories for producing the engineered viroid particles are established by cell lines obtained by introducing different target gRNA elements into the cell strain, so that the corresponding engineered viroid particles can be continuously produced in batches. According to the invention, large-scale preparation can be realized through cell expanding culture, the capacity limitation is overcome, the production process flow is simplified, and the consumption of production raw materials is reduced.
Owner:SHENZHEN CELL VALLEY BIOMEDICAL CO LTD
A method for ultra-fast virus elimination based on periodate
ActiveCN116534980BWater/sewage treatment using germicide/oligodynamic-processAgainst vector-borne diseasesPeriodate saltMedicine
A method for ultra-fast inactivation of viruses based on periodate, which relates to the technical field of waterborne virus disinfection. This method forms a mixed system by adding a periodate oxidant and a homogeneous trivalent ruthenium ion activator of transition metals into the water body containing the virus to be treated, and then rapidly and thoroughly inactivates the virus. The present invention uses a homogeneous transition metal ruthenium ion catalyst to activate periodate, which not only destroys the culturing ability of the virus, but also destroys the nucleic acids encoding protein and RNA replication in the virus, and at the same time affects the functions of attachment and injection into the host during virus proliferation, achieving the complete inactivation of the virus. This method has a wide range of applications, does not require additional energy and instrumentation, saves energy, and is simple to operate.
Owner:XIAMEN UNIV
Methods for inducing immune responses
PCT designated stageWO2025196724A1SsRNA viruses positive-senseViral antigen ingredientsVaccinationVirosome
Provided are methods for inducing immune responses against pathogens in a mammal. The methods comprise administering a single cycle adenovirus (SC-Ad) comprising a nucleic acid sequence encoding an immunogen of said pathogen to said mammal. The SC-Ad is administered by inhalation and infects a cell of said mammal, thereby causing expression of said immunogen leading to the induction of said immune response. New infectious virions are not produced. The methods may be of particular utility in vaccination for respiratory pathogens. Corresponding medical uses of the SC-Ads are also provided.
Owner:MOAT BIOTECHNOLOGY CORPORATION +1
Chemogenetic surface modified viral particles
This disclosure relates to engineered viral capsid proteins comprising functional sequence motifs and the recombinant virions comprising the same. Furthermore, this disclosure concerns intermediates for the preparation of a surface modified rAAV virion. The surface modified rAAV virions are designed to selectively and / or more efficiently deliver gene therapy. The surface modified rAAV virions, when incorporated into a recombinant virion, can be used to treat an illness characterized by genetic abnormality.
Owner:BOREA THERAPEUTICS SRL
Adeno-associated virus with engineered capsid
The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5 / 9 chimeric capsid or combinatory capsid that achieves increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.
Owner:TENAYA THERAPEUTICS INC
Purification of infective virus
PCT designated stageWO2025181504A1Component separationPeptide preparation methodsVirosomeIon exchange
The invention relates to the field of ion exchange based purification processes and provides an improved method for the purification of lipid enveloped viruses. Use of the elution solution significantly enhances the efficiency of the recovery of the infective virus, in particular intact SARS-CoV-2 virions.
Owner:PECSI TUDOMANYEGYETEM
Increased cellular stability for AAV production
PCT designated stageWO2026044087A1Virus peptidesVector-based foreign material introductionVector systemVirosome
Polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods for expressing AAV Rep proteins are provided. In certain aspects, among the provided embodiments are polynucleotides, vectors, and systems of vectors or polynucleotides, and cells including the same, that include a polynucleotide that includes a ribozyme. In certain aspects, these polynucleotides, vectors, systems of vectors or polynucleotides, cells, and methods may be used to produce higher levels of small Rep transcripts as compared to large Rep transcripts. In certain aspects, these polynucleotides, vector systems, cells, and methods may be used to produce higher levels of small Rep proteins as compared to large Rep proteins. In certain aspects, these polynucleotides, vectors, vector systems, cells, and methods may be used to produce recombinant AAV (rAAV). Increased expression of small Rep as compared to large Rep is useful in many aspects, such as, increasing total virions and increasing packaged virions during the production of rAAV.
Owner:SHAPE THERAPEUTICS INC
Methods and constructs for production of lentiviral vector
To provide a method for producing mammalian cells containing a lentiviral packaging vector.SOLUTION: A method of producing a lentiviral packaging vector-containing mammalian cells, comprising: a. transfecting a mammalian cell with a packaging vector comprising an expression cassette encoding: 1. a lentiviral regulator of expression of virion proteins (REV) gene under control of a first promoter; 2. a lentiviral envelope gene under control of a second promoter; and 3. a lentiviral group specific antigen (GAG) gene and a lentiviral polymerase (POL) gene both under control of a third promoter where the expression cassette is flanked on both the 5' and 3' ends by transposon-specific inverted terminal repeats (ITR); b. culturing the transfected mammalian cell; and c. isolating the lentiviral packaging vector-containing mammalian cell.SELECTED DRAWING: Figure 1
Owner:LONZA WALKERSVILLE INC
Method of inhibiting enveloped virus binding to target cells by incorporating P-selectin glycoprotein ligand-1 (PSGL-1) into virions
ActiveUS12194087B2SsRNA viruses negative-senseCell receptors/surface-antigens/surface-determinantsVirus BindingVirosome
Embodiments relate to a method comprising (a) expressing a vector comprising a PSGL-1 (P-selectin glycoprotein ligand-1) or a mutant thereof in a VPC (virus producing cell); and blocking a virus infection by inactivating an infectivity of a released virions from the VPC; or (b) expressing a glycoprotein or a mutant thereof in the VPC; blocking the virus infection by preventing binding of the released virions to a target cell; inactivating infectivity of the released virions; and targeting a viral infection. Other embodiments relate to (1) a broad-spectrum anti-viral product comprising: a vector expressing a glycoprotein or a mutant thereof in a VPC; and blocking a virus infection by inactivating infectivity of a released virion from the VPC; and (2) a vaccine comprising a viral particle is configured to a live attenuated or an inactivated or a non-infectious, wherein the viral particle are produced in a VPC.
Owner:GEORGE MASON UNIVERSITY
A virus structure three-dimensional reconstruction method and system
The embodiment of the application discloses a virus structure three-dimensional reconstruction method and system, the method comprises the following steps: acquiring stereoscopic data and point cloud data containing a target virus sample; separating virus particles from the point cloud data by using an optimized point cloud segmentation algorithm; separating virus regions from the stereoscopic data by using a stereoscopic data segmentation algorithm; processing the virus stereoscopic data by using a first neural network to obtain density characteristics of the virus structure; processing the virus point cloud by using a second neural network to obtain geometric characteristics of the virus surface; fusing the density characteristics and the geometric characteristics by using a multi-modal fusion model to generate unified feature representation; and reconstructing a three-dimensional model of the virus structure based on the unified feature representation. The application can accurately obtain the three-dimensional structure of the virus in a complex background, and improves the accuracy of virus three-dimensional reconstruction.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Adeno-associated virus virion for treatment of ornithine transcarbamylase deficiency
PendingJP2025020385AMetabolism disorderPeptide/protein ingredientsAntiendomysial antibodiesOrnithine transcarbamylase deficiency
To provide a novel therapeutic approach to ornithine transcarbamylase deficiency.SOLUTION: The present application provides a modified adeno-associated virus vector that efficiently transfers genes to a liver in a living body (human, for example) by expressing ornithine transcarbamylase and reducing attack from neutralizing antibodies in blood. The present application provides a modified adeno-associated virus vector or the like, expressing ornithine transcarbamylase, comprising a modified VP1 protein including an amino acid sequence with at least one of position 472, position 587, and position 706 substituted with another amino acid in the amino acid sequence of VP1 protein, and not showing a cross-reaction with a neutralizing antibody to AAV2.SELECTED DRAWING: None
Owner:JICHI MEDICAL UNIVERSITY +1
VIROBODY-LIKE DISTRIBUTION PARTICLES FOR SELF-REPLICATING RNA MOLECULES
Immunization with nucleic acids is achieved by delivering a self-replicating RNA encapsulated in a small particle. The RNA encodes an immunogen of interest, and the particle can deliver the RNA by mimicking the delivery function of a natural RNA virus. Accordingly, the invention provides a particle other than a virion for in vivo delivery of RNA to a vertebrate cell, wherein the particle comprises a delivery material that encapsulates a self-replicating RNA molecule encoding an immunogen. Such particles are useful as components of pharmaceutical compositions for immunizing subjects against various diseases.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
The present disclosure provides nucleic acid constructs (e.g., HDAd vectors), set of nucleic acid constructs (e.g., one or more HDAd vectors), HDAd virions, and HDAd virus comprising all the components for site-specifically integrating an exogenous nucleic acid into a cellular genome at a desired target sequence. The present disclosure also provides methods of using the same.
Owner:BASECAMP RESEARCH LTD
Virus structure three-dimensional reconstruction method and system
The embodiment of the invention discloses a virus structure three-dimensional reconstruction method and system. The method comprises the following steps: acquiring stereoscopic data and point cloud data containing a target virus sample; separating virus particles from the point cloud data by using an optimized point cloud segmentation algorithm; separating a virus region from the stereoscopic data by using a stereoscopic data segmentation algorithm; processing the virus stereoscopic data by using a first neural network to obtain density characteristics of a virus structure; processing the virus point cloud by using a second neural network to obtain geometric features of the virus surface; fusing the density features and the geometric features by using a multi-modal fusion model to generate unified feature representation; reconstructing a three-dimensional model of a virus structure based on unified feature representation; according to the method, the three-dimensional structure of the virus can be accurately obtained under a complex background, and the accuracy of three-dimensional reconstruction of the virus is improved.
Owner:WUHAN INST OF VIROLOGY CHINESE ACADEMY OF SCI
Stable cell lines for inducible production of raav virions
Described herein are polynucleotide constructs for inducible production of rAAV virions. Also provided are stable cell lines for inducible expression of rAAV virions that include a payload polynucleotide.
Owner:SHAPE THERAPEUTICS INC
Chimeric AAVs and their uses
The present invention provides a recombinant adeno-associated virus (rAAV) virion comprising a variant capsid polypeptide, wherein the variant capsid polypeptide comprises an alteration to an amino acid corresponding to an adeno-associated virus (AAV) capsid polypeptide amino acid selected from the list consisting of any one or more of V125, V183, N411, Y447, R490, T495 and F536 of SEQ ID NO:1; and the variant capsid polypeptide comprises an alteration to increase retrograde transport of the rAAV virion by neuronal axons.
Owner:EMUGEN THERAPEUTICS LLC
COMPOSITIONS AND METHODS OF tRNA SILENCING
Provided are compositions and methods for silencing suppressor tRNAs. Further provided are compositions and methods for silencing suppressor tRNAs during AAV production for producing virions comprising sequences coding for suppressor tRNAs.
Owner:SHAPE THERAPEUTICS INC
Use of punicalin in the preparation of a medicament for the treatment of respiratory syncytial virus
ActiveCN117159537BOrganic active ingredientsAntiviralsVirosomeAcute lower respiratory tract infection
The application discloses application of Punicalin in preparation of a medicine for resisting respiratory syncytial virus. The respiratory syncytial virus is an RNA virus, and is the most important virus body causing acute lower respiratory tract infection of children under 5 years old in the world. It is found that the Punicalin can effectively inhibit replication of the respiratory syncytial virus and effectively resist respiratory syncytial virus infection. Therefore, the Punicalin has the prospect of being developed into the medicine for resisting the respiratory syncytial virus.
Owner:NANJING UNIV OF TRADITIONAL CHINESE MEDICINE